Ascendis Pharma A/S (BVMF:A1SN34)

Market Cap	75.82B +38.3%
Revenue (ttm)	4.66B +98.0%
Net Income	-1.47B
EPS	-24.33
Shares Out	n/a
PE Ratio	n/a
Forward PE	48.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Average Volume	262
Open	76.05
Previous Close	78.57
Day's Range	76.05 - 76.05
52-Week Range	53.79 - 78.57
Beta	0.49
RSI	57.32
Earnings Date	Apr 30, 2026

About Ascendis Pharma

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 1,189
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1SN34

Financial Performance

In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.

Financial numbers in EUR